#bettertogether
Last spring, IDS and Euroimmun launched the new random access instrument IDS i20. This new automation solution followed the random access instruments IDS-i10 and IDS-iSYS already established in the market. The device was developed based on IDS’ 50 years of expertise in laboratory automation – always focusing on maximum convenience for the users and reliability. For the first time, Euroimmun staff and know-how came into play in the development of hardware and software of an IDS device and synergies were created to achieve the best possible result.
Also after its launch, the platform is a great example of the partnership between Euroimmun and IDS and their steadily interlinked activities:
Teams at sites from IDS and Euroimmun in Pouilly-en-Auxois, Boldon and Dassow are continuously validating additional tests on the device in order to make the entire portfolio available for use on the new platform soon. Owing to the integration of IDS products into the Euroimmun portfolio, our customers now have a unique and broad product range for special diagnostics at hand. For example, our chemiluminescence immunoassays (ChLIA) cover more than 200 parameters from six diagnostic areas: endocrinology, autoimmune diseases, infectious diseases, allergies, Alzheimer’s disease and therapeutic drug monitoring.
We can also provide comprehensive service and support for IDS i20 by pooling our expertise. The knowledge of our IDS colleagues is gradually passed on to the colleagues from the Euroimmun Academy so that they can train the service technicians and application specialists and thus support the IDS colleagues in the best possible way.
At the beginning of the year, product managers from IDS and Euroimmun travelled together to visit several IDS-i20 customers across Europe. They registered their status quo as part of the post-market surveillance, which ensures that a product is continuously improved over the entire product life cycle. For this cause, customer feedback and field data were collected and customer requirements were analysed based on an extensive questionnaire and during personal conversations in the labs. The results of the analysis were afterwards debated with the responsible software and hardware developers and the implementation of required optimisation at the device planned.
Thanks to the close cooperation of Euroimmun and IDS colleagues, the pooling of our know-how and our intertwined activities, we can optimise our portfolio and create innovations for the future.
